Skip to content

Comparison of two drugs in the treatment of a low risk treatable malignancy

Randomised trial of pulsed Actinomycin D versus MTX infusion in low risk gestational trophoblastic neoplasia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/11/003120
Enrollment
150
Registered
2012-11-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Low risk Gestational Trophoblastic Disease

Interventions

Intervention1: Methotrexate Infusion: MTX 300mg/m² in 500 ml of normal saline given as an IV infusion over six hours followed by folinic acid 15 mg per orally every 6 hours for four doses starting 24

Sponsors

Christian Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with abnormal hCG regression following any type of pregnancy (molar, term, abortion,ectopic) ie (1)hCG plateau for 4 consecutive values over 3 weeks (2)hCG rise of >10% for 3 values over 2 weeks (3)hCG persistence 6 months after molar pregnancy evacuation For staging and pretreatment evaluation, all patients will undergo complete physical and pelvic examination, complete blood cell count, urinalysis, liver and renal function tests, and chest x-ray. Ultrasonography and/or computed tomographic scanning will be performed when clinically indicated. Diagnosis, staging, and risk scoring will be as per International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria for diagnosis and staging for GTN. Low risk gestational trophoblastic disease FIGO score <6

Exclusion criteria

Exclusion criteria: •Choriocarcinoma •Any patient with renal, hepatic,haematological disease •Pregnancy •Prognostic score > 6

Design outcomes

Primary

MeasureTime frame
Primary remission rate or Complete response (Proportion)Timepoint: 5years

Secondary

MeasureTime frame
Time to cure Number of cycles required for complete response Toxicity & Side effects Cost of treatment Timepoint: 5 years

Countries

India

Contacts

Public ContactAnitha Thomas

Christian Medical College, Vellore, India

anithomas@cmcvellore.ac.in9789683006

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026